XIFAXAN® (rifaximin) 550 mg tablets are contraindicated in patients with a hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN.
The USFDA's tentative approval means Biocon Pharma's Rifaximin 550 mg meets regulatory requirements but cannot be marketed in ...
Bangalore: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, in partnership with ...
RALEIGH, N.C., Feb 23, 2010 (BUSINESS WIRE) -- Salix Pharmaceuticals, Ltd. /quotes/comstock/15*!slxp/quotes/nls/slxp (SLXP 28.40, +4.15, +17.11%) today reported that ...
Please provide your email address to receive an email when new articles are posted on . In a composite of three trials, rifaximin provided a durable and significant improvement in bloating in patients ...
BRIDGEWATER, N.J., Oct. 1, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") along with its wholly owned subsidiary, Salix Pharmaceuticals ("Salix"), ...
LAVAL, Quebec, May 6, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") along with its wholly owned subsidiary, Salix Pharmaceuticals ("Salix"), ...
Bausch Health BHC, along with its gastroenterology business, Salix Pharmaceuticals, Inc., announced that it has filed a lawsuit against Amneal Pharmaceuticals AMRX and its subsidiaries. The lawsuit ...
Bausch Health, along with its gastroenterology business, Salix Pharmaceuticals, has filed a lawsuit in the United States District Court for the District of New Jersey against Amneal Pharmaceuticals of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback